Trademark: 88469477
Word
HYLEUKIN-7
Status
Dead
Status Code
606
Status Date
Monday, January 25, 2021
Serial Number
88469477
Mark Type
4000
Filing Date
Wednesday, June 12, 2019
Published for Opposition
Tuesday, April 28, 2020
Abandoned Date
Monday, January 25, 2021

Trademark Owner History
Genexine, Inc. - Owner At Publication

Classifications
5 Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent for medical purposes, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; Vaccines; Pharmaceutical preparations for the treatment of lymphopenia; Immunoglobulin fusion protein pharmaceutical preparations, namely, antibodyfusion proteins for the treatment of cancer
HYLEUKIN- SEVEN

Trademark Events
Jan 25, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Jan 25, 2021
Abandonment - No Use Statement Filed
Jun 23, 2020
Noa E-Mailed - Sou Required From Applicant
Apr 28, 2020
Official Gazette Publication Confirmation E-Mailed
Apr 28, 2020
Published For Opposition
Apr 8, 2020
Notification Of Notice Of Publication E-Mailed
Mar 25, 2020
Assigned To Lie
Mar 19, 2020
Approved For Pub - Principal Register
Mar 18, 2020
Examiner's Amendment Entered
Mar 18, 2020
Notification Of Examiners Amendment E-Mailed
Mar 18, 2020
Examiners Amendment E-Mailed
Mar 18, 2020
Examiners Amendment -Written
Feb 24, 2020
Teas Change Of Correspondence Received
Feb 24, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Feb 24, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 24, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Feb 24, 2020
Teas Change Of Owner Address Received
Feb 24, 2020
Teas/Email Correspondence Entered
Feb 24, 2020
Correspondence Received In Law Office
Feb 24, 2020
Teas Response To Office Action Received
Aug 26, 2019
Notification Of Non-Final Action E-Mailed
Aug 26, 2019
Non-Final Action E-Mailed
Aug 26, 2019
Non-Final Action Written
Aug 20, 2019
Assigned To Examiner
Jun 24, 2019
New Application Office Supplied Data Entered In Tram
Jun 15, 2019
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24